TY  - JOUR
AU  - Pascual, Tomás
AU  - Martin, Miguel
AU  - Fernández-Martínez, Aranzazu
AU  - Paré, Laia
AU  - Alba, Emilio
AU  - Rodríguez-Lescure, Álvaro
AU  - Perrone, Giuseppe
AU  - Cortés, Javier
AU  - Morales, Serafín
AU  - Lluch, Ana
AU  - Urruticoechea, Ander
AU  - González-Farré, Blanca
AU  - Galván, Patricia
AU  - Jares, Pedro
AU  - Rodriguez, Adela
AU  - Chic, Nuria
AU  - Righi, Daniela
AU  - Cejalvo, Juan Miguel
AU  - Tonini, Giuseppe
AU  - Adamo, Barbara
AU  - Vidal, Maria
AU  - Villagrasa, Patricia
AU  - Muñoz, Montserrat
AU  - Prat, Aleix
PY  - 2019
DO  - 10.3389/fonc.2019.00303
SN  - 2234-943X
UR  - http://hdl.handle.net/10668/13987
T2  - Frontiers in oncology
AB  - Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no...
LA  - en
KW  - PAM50
KW  - breast cancer
KW  - gene expression
KW  - intrinsic subtype
KW  - non-luminal
TI  - A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
TY  - research article
VL  - 9
ER  -